Is Travere Therapeutics, Inc. (TVTX) A Good Stock To Buy Now?

Is TVTX a bully banal to buy? We came crossed a bullish thesis on Travere Therapeutics, Inc. connected Biotech Distilled's Substack. In this article, we volition summarize the bulls' thesis connected TVTX. Travere Therapeutics, Inc.'s stock was trading astatine $47.08 arsenic of June 8th. TVTX's guardant P/E was 63.29 according to Yahoo Finance.

Nestor Rizhniak/Shutterstock.com

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to radical surviving with uncommon kidney and metabolic diseases successful the United States. TVTX is presented arsenic transitioning decisively into a profitability inflection phase, driven by accelerating commercialized execution of FILSPARI and emerging pipeline optionality crossed uncommon kidney diseases.

Read More: 15 AI Stocks That Are Quietly Making Investors Rich

Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential

The company's Q1 2026 results reenforce a strengthening request trajectory, with FILSPARI U.S. nett income reaching $105.2 million, up 88% year-over-year, marking its archetypal 4th supra the $100 cardinal threshold connected a standalone basis.

Growth momentum is further supported by grounds diligent request successful IgAN, with 993 caller diligent commencement forms versus anterior highs, indicating that REMS-related prescribing friction is progressively absorbed and request remains intact contempt regulatory complexity. The FSGS motorboat adds a 2nd maturation vector, with contiguous reimbursed prescriptions and diligent commencement forms recorded wrong days of approval, signaling meaningful pent-up request successful a antecedently untreated indication.

Importantly, Travere delivered its archetypal non-GAAP profitable quarter, reporting $4.1 cardinal successful nett income versus a $16.9 cardinal nonaccomplishment a twelvemonth earlier, reflecting a $21 cardinal year-over-year plaything and earlier-than-expected operating leverage versus anterior 2027 profitability expectations. Although GAAP losses persist owed to royalty obligations and stock-based compensation, underlying economics are improving arsenic standard expands.

The concern continues to make beardown gross publication from FILSPARI contempt a 15–17% Ligand royalty drag, portion inactive demonstrating improving currency subject with operating pain trending unchangeable and liquidity of astir $265 million, supplemented by milestone inflows that widen runway beyond 12 months.

Pipeline upside remains significant, with pegtibatinase re-dosing underway and HARMONY readout expected successful 2H 2027, offering further semipermanent optionality. Key upcoming catalysts see NKF objective information successful May 2026, Japan filing advancement done spouse Chugai successful 2026, and continued enlargement crossed IgAN and FSGS. Overall, Travere is positioned arsenic a high-growth uncommon illness level with accelerating profitability, aggregate near-term catalysts, and a structurally improving commercialized base, with upside imaginable driven by continued FILSPARI scaling and long-dated pipeline worth realization.